Similar articles

Abstract: Objective: The aim of our meta-analysis was to assess the effects of antiepileptic drugs on bone mineral density and bone metabolism in epileptic children. Methods: Searches of PubMed and Web of Science were undertaken to identify studies evaluating the association between antiepileptic drugs and bone mineral density and bone metabolism. Results: A total of 22 studies with 1492 subjects were included in our research. We identified: (1) a reduction in bone mineral density at lumbar spine (standardized mean difference (SMD)=−0.30, 95% confidence interval (CI) [−0.61, −0.05]), trochanter (mean difference (MD)=−0.07, 95% CI [−0.10, −0.05]), femoral neck (MD=−0.05, 95% CI [−0.09, −0.02]), and total body bone mineral density (MD=−0.33, 95% CI [−0.51, −0.15]); (2) a reduction in 25-hydroxyvitamin D (MD=−3.37, 95% CI [−5.94, −0.80]) and an increase in serum alkaline phosphatase (SMD=0.71, 95% CI [0.38, 1.05]); (3) no significant changes in serum parathyroid hormone, calcium, or phosphorus. Conclusions: Our meta-analysis suggests that treatment with antiepileptic drugs may be associated with decreased bone mineral density in epileptic children.

抗癫痫药物影响儿童骨矿物质密度及骨代谢的荟萃分析

[1]Akin, R., Okutan, V., Sarici U., et al., 1998. Evaluation of bone mineral density in children receiving antiepileptic drugs. Pediatr. Neurol., 19(2):129-131.

[2]Babacan, O., Karaoglu, A., Vurucu, S., et al., 2012. May long term oxcarbazepine treatment be lead to secondary hyperparathyroidism? J. Clin. Neurol., 8(1):65-68.

[3]Babayigit, A., Dirik, E., Bober, E., et al., 2006. Adverse effects of antiepileptic drugs on bone mineral density. Pediatr. Neurol., 35(3):177-181.

[4]Baer, M.T., Kozlowski, B.W., Blyler, E.M., et al., 1997. Vitamin D, calcium, and bone status in children with developmental delay in relation to anticonvulsant use and ambulatory status. Am. J. Clin. Nutr., 65(4):1042-1051.

[5]Begley, C.E., Famulari, M., Annegers, J.F., et al., 2000. The cost of epilepsy in the United States: an estimate from population-based clinical and survey data. Epilepsia, 41(3):342-351.

[6]Bergqvist, A.G.C., Schall, J.I., Stallings, V.A., 2007. Vitamin D status in children with intractable epilepsy, and impact of the ketogenic diet. Epilepsia, 48(1):66-71.

[7]Cerveny, L., Svecova, L., Anzenbacherova, E., et al., 2007. Valproic acid induces CYP3A4 and MDR1 gene expression by activation of constitutive androstane receptor and pregnane X receptor pathways. Drug Metab. Dispos., 35(7):1032-1041.

[8]Chung, S., Ahn, C., 1994. Effects of anti-epileptic drug therapy on bone mineral density in ambulatory epileptic children. Brain Dev., 16(5):382-385.

[9]Dent, C.E., Richens, A., Rowe, D.J., et al., 1970. Osteomalacia with long-term anticonvulsant therapy in epilepsy. Br. Med. J., 4(5727):69-72.

[10]Dimić, M., Dimić, A., Milosević, Z., et al., 2013. Bone mineral density in children with long-term antiepileptic therapy. Srp. Arh. Celok. Lek., 141(5-6):329-332 (in Serbian).

[11]Ecevit, C., Aydoğan, A., Kavakli, T., et al., 2004. Effect of carbamazepine and valproate on bone mineral density. Pediatr. Neurol., 31(4):279-282.

[12]El-Hajj Fuleihan, G., Dib, L., Yamout, B., et al., 2008. Predictors of bone density in ambulatory patients on antiepileptic drugs. Bone, 43(1):149-155.

[13]Erbayat Altay, E., Serdaroglu, A., Tumer, L., et al., 2000. Evaluation of bone mineral metabolism in children receiving carbamazepine and valproic acid. J. Pediatr. Endocrinol. Metab., 13(7):933-939.

[14]Feldkamp, J., Becker, A., Witte, O.W., et al., 2000. Long-term anticonvulsant therapy leads to low bone mineral density-evidence for direct drug effects of phenytoin and carbamazepine on human osteoblast-like cells. Exp. Clin. Endocrinol. Diabetes, 108(1):37-43.

[15]Gniatkowska-Nowakowska, A., 2010. Fractures in epilepsy children. Seizure, 19(6):324-325.

[16]Hannan, M.T., Litman, H.J., Araujo, A.B., et al., 2008. Serum 25-hydroxyvitamin D and bone mineral density in a racially and ethnically diverse group of men. J. Clin. Endocrinol. Metab., 93(1):40-46.

[17]Kafali, G., Erselcan, T., Tanzer, F., 1999. Effect of antiepileptic drugs on bone mineral density in children between ages 6 and 12 years. Clin. Pediatr., 38(2):93-98.

[18]Karceski, S.C., 2007. Seizure medications and their side effects. Neurology, 69(22):E27-E29.

[19]Keck, E., Gollnick, B., Reinhardt, D., et al., 1982. Calcium metabolism and vitamin D metabolite levels in children receiving anticonvulsant drugs. Eur. J. Pediatr., 139(1):52-55.

[20]Kumandas, S., Koklu, E., Gümüs, H., et al., 2006. Effect of carbamezapine and valproic acid on bone mineral density, IGF-I and IGFBP-3. J. Pediatr. Endocrinol. Metab., 19(4):529-534.

[21]Lee, R.H., Lyles, K.W., Colón-Emeric, C., 2010. A review of the effect of anticonvulsant medications on bone mineral density and fracture risk. Am. J. Geriatr. Pharmacother., 8(1):34-46.

[22]Liberati, A., Altman, D.G., Tetzlaff, J., et al., 2009. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. Ann. Intern. Med., 151(4):W65-W94.

[23]Meier, C., Kraenzlin, M.E., 2011. Antiepileptics and bone health. Ther. Adv. Musculoskelet. Dis., 3(5):235-243.

[24]Mikati, M.A., Dib, L., Yamout, B., et al., 2006. Two randomized vitamin D trials in ambulatory patients on anticonvulsants: impact on bone. Neurology, 67(11):2005-2014.

[25]Nettekoven, S., Ströhle, A., Trunz, B., et al., 2008. Effects of antiepileptic drug therapy on vitamin D status and biochemical markers of bone turnover in children with epilepsy. Eur. J. Pediatr., 167(12):1369-1377.

[26]Nicolaidou, P., Georgouli, H., Kotsalis, H., et al., 2006. Effects of anticonvulsant therapy on vitamin D status in children: prospective monitoring study. J. Child. Neurol., 21(3):205-209.

[27]Oner, N., Kaya, M., Karasalihoglu, S., et al., 2004. Bone mineral metabolism changes in epileptic children receiving valproic acid. J. Paediatr. Child Health, 40(8):470-473.

[28]Pack, A.M., Morrell, M.J., 2001. Adverse effects of antiepileptic drugs on bone structure: epidemiology, mechanisms and therapeutic implications. CNS Drugs, 15(8):633-642.

[29]Pack, A.M., Morrell, M.J., Randall, A., et al., 2008. Bone health in young women with epilepsy after one year of antiepileptic drug monotherapy. Neurology, 70(18):1586-1593.

[30]Petty, S.J., Paton, L.M., O'Brien, T.J., et al., 2005. Effect of antiepileptic medication on bone mineral measures. Neurology, 65(9):1358-1365.

[31]Rauchenzauner, M., Griesmacher, A., Tatarczyk, T., et al., 2010. Chronic antiepileptic monotherapy, bone metabolism, and body composition in non-institutionalized children. Dev. Med. Child Neurol., 52(3):283-288.

[32]Razazizan, N., Mirmoeini, M., Daeichin, S., et al., 2013. Comparison of 25-hydroxy vitamin D, calcium and alkaline phosphatase levels in epileptic and non-epileptic children. Acta. Neurol. Taiwan, 22(3):112-116.

[33]Reid, I.R., Bolland, M.J., Grey, A., 2014. Effects of vitamin D supplements on bone mineral density: a systematic review and meta-analysis. Lancet, 383(9912):146-155.

[34]Salimipour, H., Kazerooni, S., Seyedabadi, M., et al., 2013. Antiepileptic treatment is associated with bone loss: difference in drug type and region of interest. J. Nucl. Med. Technol., 41(3):208-211.

[35]Shellhaas, R.A., Joshi, S.M., 2010. Vitamin D and bone health among children with epilepsy. Pediatr. Neurol., 42(6):385-393.

[36]Sheth, R.D., Hermann, B.P., 2008. Bone in idiopathic and symptomatic epilepsy. Epilepsy Res., 78(1):71-76.

[37]Sheth, R.D., Wesolowski, C.A., Jacob, J.C., et al., 1995. Effect of carbamazepine and valproate on bone mineral density. J. Pediatr., 127(2):256-262.

[38]Sheth, R.D., Binkley, N., Hermann, B.P., 2008. Progressive bone deficit in epilepsy. Neurology, 70(3):170-176.

[39]Souverein, P.C., Webb, D.J., Petri, H., et al., 2005. Incidence of fractures among epilepsy patients: a population-based retrospective cohort study in the General Practice Research Database. Epilepsia, 46(2):304-310.

[40]Turan, M.I., Cayir, A., Ozden, O., et al., 2014. An examination of the mutual effects of valproic acid, carbamazepine, and phenobarbital on 25-hydroxyvitamin D levels and thyroid function tests. Neuropediatrics, 45(1):16-21.

[41]Verrotti, A., Greco, R., Latini, G., et al., 2002. Increased bone turnover in prepubertal, pubertal, and postpubertal patients receiving carbamazepine. Epilepsia, 43(12):1488-1492.

[42]Verrotti, A., Coppola, G., Parisi, P., et al., 2010. Bone and calcium metabolism and antiepileptic drugs. Clin. Neurol. Neurosurg., 112(1):1-10.

[43]Vestergaard, P., 2005. Epilepsy, osteoporosis and fracture risk—a meta-analysis. Acta Neurol. Scand., 112(5):277-286.

[44]Voudris, K., Moustaki, M., Zeis, P.M., et al., 2002. Alkaline phosphatase and its isoenzyme activity for the evaluation of bone metabolism in children receiving anticonvulsant monotherapy. Seizure, 11(6):377-380.

[45]Voudris, K.A., Attilakos, A., Katsarou, E., et al., 2005. Early alteration in bone metabolism in epileptic children receiving carbamazepine monotherapy owing to the induction of hepatic drug-metabolizing enzymes. J. Child. Neurol., 20(6):513-516.